AstraZeneca pulls cancer drug application in Europe
LONDON (Reuters) - AstraZeneca has pulled an application seeking European approval to sell its experimental cancer drug cediranib in combination with chemotherapy to treat ovarian cancer because of late-stage questions raised by regulators reviewing the product.
However, the British company said on Wednesday that cediranib, a so-called VEGFR inhibitor, remained an important pipeline medicine and the decision did not affect its ongoing development in combination tests alongside other drugs.
(Reporting by Ben Hirschler; editing by Jason Neely)
© Copyright Reuters Ltd. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Reuters Ltd.
